Shanghai, China – On April 1, Flashpoint™ Renal Artery RF Ablation Catheter ("Flashpoint™ Catheter "), in-house developed by Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP"), was granted the Green-Path by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval. Combined with Renal Artery RF Generator and Irrigation Pump, Flashpoint™ Catheter is indicated for the treatment of drug resistant hypertension by renal artery sympathetic denervation. Its CFDA Green-Path may shorten the approval time so that Flashpoint™ Catheter will be launched in the market earlier than expected to benefit patients with drug resistant hypertension.
The innovative Green-Path for CFDA approval was an important approach introduced by the government authority to encourage the innovations of medical devices and promote the application of new technologies in the healthcare industry. In 2015, MicroPort® EP's Columbus™ 3D EP Navigation System and FireMagic™ 3D Irrigated Ablation Catheter also gained the CFDA Green-Path.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.